NanoViricides' antiviral NV-387 gets FDA Orphan Drug Designation for measles treatment.

NanoViricides announced that its antiviral drug NV-387 has received Orphan Drug Designation from the US FDA for treating measles. This designation offers benefits like tax credits, fee exemptions, and up to seven years of market exclusivity, potentially speeding regulatory approval. NV-387 is notable for strong activity against lethal measles in preclinical models and is also being considered for a Rare Pediatric Disease Drug designation, which could further accelerate FDA review. The drug has shown promise against other viruses including RSV, COVID-19, and influenza.